

Remarks

Currently Claims 1-6 are pending. Applicants note that original claims 6-7 were erroneously mis-numbered as claim claims 4 and 5. Applicants have correctly referred to these claims as claims 6-7 in the instant amendment. Applicants request that the Examiner acknowledge the correction of claim numbering.

Claim 7 is canceled.


Claims 1 and 3-6 are amended herein. Claim 1 is amended to correct to change plural to singular. Claims 3-6 are amended to remove multiple dependencies to reduce claim fees. The foregoing amendments do not narrow the scope of the claims and are not made for reasons of patentability. No new matter is added.

Applicants have also amended the specification to correct a typographical error in the title, to recite priority application information and to provide an abstract on a separate page.

Entry of the foregoing amendments is respectfully requested.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case, if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

1 Sept
Date: ~~20 July~~, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988
email: Lorie.A.Morgan@gsk.com